Tremfya Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The tremfya drug market size is projected to be USD 5.16 billion in 2025, USD 6.43 billion in 2026, and reach USD 10.18 billion by 2031, growing at a CAGR of 9.61% from 2026 to 2031. This report is Segmented by Application (Plaque Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease), Route of Administration (Subcutaneous Injection, Intravenous Infusion), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Tremfya Drug Market Trends and Insights

Expanding Label Into Inflammatory Bowel Disease

The Tremfya drug market gained a wider clinical base when the FDA approved ulcerative colitis in September 2024 and Crohn's disease in March 2025, which moved guselkumab from a narrower immunology profile into a broader cross-specialty biologic position. The Tremfya drug market then gained support from the GALAXI-2 and GALAXI-3 Phase 3 results, which showed superiority versus ustekinumab across clinical remission, endoscopic response, and endoscopic remission at week 48 in Crohn's disease. That evidence matters because the Tremfya drug market is no longer competing only on class familiarity, and it now carries a head-to-head efficacy message in a setting where treatment sequencing often follows prior biologic exposure. The Tremfya drug market also benefits from the maintenance-phase pattern highlighted in the Crohn's disease positioning literature, where more than 90% of patients meeting primary endpoints did so without steroid dependence, a metric that aligns with the shift toward deeper disease control in gastroenterology. European approvals for ulcerative colitis in April 2025 and for Crohn's disease in May 2025 reduced the gap between the United States and Europe and supported a more synchronized international rollout of the Tremfya drug market. As a result, the Tremfya drug market is moving toward a revenue base that is less tied to plaque psoriasis alone and more balanced across chronic gastrointestinal use, where treatment duration and specialist follow-up are both structurally high.

Durable IL-23 Differentiation Versus Legacy Biologics

The Tremfya drug market retains a differentiated profile because guselkumab selectively inhibits the IL-23 p19 subunit and also binds CD64, which sets it apart from broader IL-12/23 and TNF-targeting biologics. The Tremfya drug market also carries the benefit of a longer commercial and clinical history in psoriasis, which gives prescribers years of familiarity in safety, persistence, and switching behavior. In moderate psoriasis with high-impact site involvement, the Phase 3b SPECTREM study showed that 74.2% of adults reached IGA 0/1 clearance on guselkumab versus 12.4% on placebo, which opens use earlier in the disease course for patients who were often left on repeated topical escalation. That earlier entry point matters because the Tremfya drug market can extend beyond severe cases and address patients whose disease burden is driven by location and daily impact rather than only by body surface area. The May 2026 FDA label expansion adds another clinical distinction because guselkumab is now the only IL-23 inhibitor with evidence of structural joint damage inhibition in active psoriatic arthritis. This keeps the Tremfya drug market relevant in rheumatology as well as dermatology, where prevention of radiographic progression carries long-term weight in treatment choice.

Premium Biologic Pricing and Payer Prior Authorization Pressure

The Tremfya drug market still faces access friction because guselkumab sits in the specialty biologic category, and coverage rules in that category are shaped by utilization controls and formal review pathways. In ulcerative colitis, UnitedHealthcare's commercial policy requires documented inadequate response to conventional therapy and or prior biologic or JAK inhibitor therapy before coverage is approved, which shows how restrictive entry can be even after label expansion. The Tremfya drug market therefore depends not only on physician preference but also on how quickly clinics can gather records, submit authorizations, and respond to follow-up payer requests. That burden is heavier in community practices than in large academic centers, so the Tremfya drug market can see slower real-world starts than trial data alone would suggest. These delays matter because treatment initiation and persistence are closely linked in chronic immune disease, especially when patients are moving across prior therapies and complex benefit designs. As a result, payer management remains one of the clearest near-term limits on how quickly the Tremfya drug market can convert new approvals into realized prescribing volume.

Other drivers and restraints analyzed in the detailed report include:

• Pediatric and Multi-Label Expansion Supports Longer Lifecycle
• Site-of-Care Flexibility Improves Access and Persistence
• Intensifying Competition From IL-23, IL-17, and TYK2 Therapies

Segment Analysis

Plaque psoriasis accounted for 86.31% of the Tremfya drug market in 2025, which shows how strongly the brand was still anchored in dermatology before the newer gastrointestinal approvals began to scale. That concentration was supported by long-standing formulary familiarity, broad specialist use, and guideline recognition in psoriasis care, which gave the Tremfya drug market a durable base before IBD started contributing meaningful incremental volume. Psoriatic arthritis remained the second-largest application and gained added importance in May 2026, when the FDA label was expanded to include structural joint damage inhibition in active disease. That label depth matters for rheumatologists because long-term management is shaped not only by symptom control but also by protection against irreversible radiographic progression. Crohn's disease is the fastest-growing application and is forecast to expand at an 11.38% CAGR through 2026-2031, supported by the March 2025 FDA approval, the May 2025 European Commission authorization, and the week 48 GALAXI results against ustekinumab.

Ulcerative colitis remains the third application by current revenue contribution, and its profile strengthened after the FDA first approved IV induction in September 2024 and later approved the subcutaneous induction option in September 2025. Long-term support for that application is visible in the QUASAR extension, where maintenance regimens sustained symptomatic, endoscopic, and histologic efficacy through week 92, which helps the Tremfya drug industry build confidence beyond the induction window. Other approved uses, including palmoplantar pustulosis and erythrodermic psoriasis in Japan, continue to add a smaller but stable revenue layer to the Tremfya drug market. Over the forecast period, the Tremfya drug market is likely to show a lower dependence on plaque psoriasis alone as Crohn's disease and ulcerative colitis move from early specialist adoption into broader community gastroenterology practice. That mix shift supports volume growth, but it also exposes the brand to a more step-therapy-intensive payer environment and a different balance between medical-benefit and pharmacy-benefit reimbursement.

Complete Report Scope:

• By Application
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Crohn's Disease
  • Other Applications
• By Route of Administration
  • Subcutaneous Injection
  • Intravenous Infusion
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 42.22% of the Tremfya drug market in 2025, and the region remains the largest geographic contributor because the United States secured early approvals across indications and has the deepest specialty pharmacy infrastructure in routine use. The regional position of the Tremfya drug market is also supported by the TREMFYA withMe support model, which helps patients navigate affordability, onboarding, and adherence across chronic treatment cycles. Johnson & Johnson's 2025 annual report shows that Tremfya contributed materially to company revenue, which underlines how central the United States is to the global scale of the Tremfya drug market. Canada benefits from the brand's established psoriasis and psoriatic arthritis presence, while Mexico remains smaller because biologic penetration is still constrained by infrastructure and funding patterns. This leaves North America with the broadest commercial base in the Tremfya drug market, but it also leaves the region most exposed to prior authorization intensity and benefit-design complexity.

Europe is the second-largest regional block in the Tremfya drug market, and its position improved after the European Commission approved ulcerative colitis in April 2025, Crohn's disease in May 2025, SC induction in ulcerative colitis in October 2025, and pediatric plaque psoriasis in December 2025. The United Kingdom added a separate post-Brexit path when the MHRA approved guselkumab for Crohn's disease and ulcerative colitis in May 2025. The Tremfya drug market still faces a slower revenue conversion cycle in Europe because national HTA bodies and price negotiations can delay broad reimbursement even after regulatory approval. Even with that friction, Europe remains important because treatment goals in gastroenterology increasingly emphasize endoscopic remission, which fits the way the Tremfya drug market is being positioned in IBD.

Asia-Pacific is the fastest-growing geography in the Tremfya drug market and is forecast to expand at a 10.65% CAGR during 2026-2031 as recent approval milestones widen use beyond psoriasis into IBD. Japan is central to that pattern because it approved guselkumab for ulcerative colitis in March 2025, Crohn's disease in June 2025, and SC induction for ulcerative colitis in February 2026, which gives the Tremfya drug market a more complete route and indication profile in a major high-income market. China adds scale potential because guselkumab already has approval breadth across plaque psoriasis and IBD-related use, which supports longer-term expansion of the Tremfya drug market in a large treated population base. The Middle East and Africa remain early in adoption, with higher-income Gulf markets leading use while the rest of the region contributes limited volume. South America also remains smaller, but Brazil stands out in the Tremfya drug market because approvals in ulcerative colitis and Crohn's disease create a base for biologic use in gastroenterology. Taken together, these patterns show a market that is still led by North America, well supported by Europe, and most rapidly widened by Asia-Pacific.

List of Companies Covered in this Report:

• Johnson & Johnson

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support